TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) have received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $40.67.

TGTX has been the topic of a number of recent research reports. StockNews.com lowered shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 31st. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a research report on Wednesday, January 15th. Finally, TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company.

TG Therapeutics Price Performance

TGTX stock opened at $33.09 on Friday. The business’s fifty day moving average price is $31.44 and its 200 day moving average price is $26.92. TG Therapeutics has a 12-month low of $12.84 and a 12-month high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market capitalization of $5.15 billion, a PE ratio of -330.87 and a beta of 2.26.

Insider Activity at TG Therapeutics

In related news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the sale, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sagar Lonial sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,358 shares of company stock valued at $781,497 over the last quarter. 10.50% of the stock is owned by insiders.

Institutional Trading of TG Therapeutics

A number of large investors have recently made changes to their positions in TGTX. HighTower Advisors LLC lifted its stake in TG Therapeutics by 19.0% in the fourth quarter. HighTower Advisors LLC now owns 14,912 shares of the biopharmaceutical company’s stock valued at $449,000 after buying an additional 2,386 shares during the last quarter. Edgestream Partners L.P. acquired a new position in shares of TG Therapeutics in the 4th quarter valued at $1,618,000. E Fund Management Co. Ltd. raised its position in TG Therapeutics by 7.8% in the 4th quarter. E Fund Management Co. Ltd. now owns 23,554 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 1,711 shares during the last quarter. Inceptionr LLC acquired a new stake in TG Therapeutics during the 4th quarter worth $263,000. Finally, Raymond James Financial Inc. purchased a new position in TG Therapeutics during the 4th quarter worth $14,508,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.